Edition:
United Kingdom

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

12.19USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$12.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
700,769
52-wk High
$17.60
52-wk Low
$11.58

Chart for

About

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $2,478.36
Shares Outstanding(Mil.): 164.57
Dividend: --
Yield (%): --

Financials

  FOLD.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.46 -- --
ROI: -24.93 15.07 14.61
ROE: -69.35 16.59 16.33

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

13 Aug 2018

UPDATE 1-Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

13 Aug 2018

Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

13 Aug 2018

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

10 Aug 2018

UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

10 Aug 2018

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

10 Aug 2018

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

08 May 2018

Competitors

  Price Chg
Sanofi SA (SASY.PA) €75.49 +0.88
Shire PLC (SHP.L) 4,572.50 +57.00
Shire PLC (3159084.L) -- --
Actelion Ltd (ATLN.S) -- --

Earnings vs. Estimates